Scarica l'app Stockscreener
803.17
2.49%
19.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$783.65
Aprire:
$788.92
Volume 24 ore:
974.10K
Relative Volume:
1.03
Capitalizzazione di mercato:
$84.91B
Reddito:
$14.34B
Utile/perdita netta:
$4.50B
Rapporto P/E:
19.32
EPS:
41.5626
Flusso di cassa netto:
$3.77B
1 W Prestazione:
+2.25%
1M Prestazione:
+5.83%
6M Prestazione:
+43.03%
1 anno Prestazione:
+19.12%
Intervallo 1D:
$785.00
$806.18
Intervallo di 1 settimana:
$745.07
$806.18
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Cibc World Market Inc. Has $8.85 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Allergy Data And Dupixent Insights Shape Immunology Growth Story - simplywall.st
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens - Benzinga
Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts? - Insider Monkey
HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $990 From $985, Maintains Buy Rating - marketscreener.com
Krilogy Financial LLC Invests $1.18 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Illinois Municipal Retirement Fund Buys 2,599 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron, Samsung Bioepis Settle Eylea Biosimilar Patent Case - Bloomberg Law News
Regeneron, Samsung Bioepis Settle Eye Med Patent Claims - Law360
Sanofi and Regeneron Advance Itepekimab Bet With Completed Phase 2 Bronchiectasis Trial - TipRanks
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026? - TradingView
Rhumbline Advisers Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Leuthold Group LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
115,028 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Sound Shore Management Inc CT - MarketBeat
Prospera Financial Services Inc Has $4.93 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Block Graft Market Is Going to Boom | Regeneron Pharmaceuticals • Novartis • Pfizer - openPR.com
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges - Finviz
Samsung Bioepis to launch ophthalmology biosimilar in U.S. next year - Yonhap News Agency
Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $77,853.00 in Stock - MarketBeat
Insider Selling: Arthur Ryan Sells Shares of Regeneron Pharmaceu - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) SVP Sells $1,585,066.72 in Stock - MarketBeat
How to watch Regeneron's March healthcare investor talks - Stock Titan
Regeneron Announces Investor Conference Presentations - The Manila Times
Regeneron Pharmaceuticals Officer Sells Over $1.5 Million in Company Stock - TradingView
A Look At Regeneron (REGN) Valuation As Recent Share Weakness Meets An 8.1% Undervaluation Estimate - simplywall.st
Trading Systems Reacting to (REGN) Volatility - Stock Traders Daily
Skylands Capital LLC Acquires New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ING Groep NV Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Baader Bank Aktiengesellschaft - MarketBeat
The Zacks Analyst Blog Highlights NVIDIA, Amazon.com, Regeneron, National Presto and AXIL - Yahoo Finance
Evommune’s Atopic Dermatitis Data Competitive With Dupixent - Citeline News & Insights
Top Stock Reports for NVIDIA, Amazon & Regeneron - Nasdaq
Regeneron Pipeline Progress Continues but Near-Term Visibility Remains Limited, RBC Says - marketscreener.com
Sanofi (SNY) Collaborates on New Allergy Treatment Insights - GuruFocus
Regeneron to present Phase 3 data on novel allergy antibodies at AAAAI - Investing.com Canada
United States Biotechnology Market to hit US$ 1.5 Trillion - openPR.com
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy - The Manila Times
Regeneron Pharmaceuticals showcases 36 breakthroughs at AAAAI26 - Traders Union
Regeneron Rose 3% This Week. Here’s Where the Stock Could Be Headed in 2026 - TIKR.com
New antibody cocktails for cat and birch allergies show first Phase 3 data - Stock Titan
Should Regeneron’s (REGN) EYLEA HD Milestones and Buybacks Reshape Its Long-Term Investment Narrative? - simplywall.st
Envestnet Asset Management Inc. Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ProShare Advisors LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Oppenheimer & Co. Inc. Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Guggenheim Raises Price Target for Regeneron Pharmaceuticals (RE - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $975.00 Price Target at Guggenheim - MarketBeat
Guggenheim raises Regeneron stock price target to $975 on Dupixent growth - Investing.com
Candriam S.C.A. Has $95.30 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bessemer Group Inc. Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Savant Capital LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sanofi (SNY) Strengthens Shareholder Returns Amid Robust 2025 Performance and Long-Term Growth Outlook - Finviz
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
5.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):